Citius Pharmaceuticals Inc. Common Stock (CTXR)
Stock · NASDAQ · Health Care
$0.46as of 10/16/2026
Price chart
Active signals
CTXR Signal Track Record
How signals performed across all stocks →What CTXR's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 39 | -9.7% | 33% | October 6, 2026 |
| Bollinger Band Breakdown | 20 | +0.7% | 55% | September 28, 2026 |
| Bollinger Band Breakout | 19 | -4.8% | 47% | July 30, 2026 |
| 200-Day Moving Average TouchActive now | 11 | -12.9% | 36% | December 4, 2025 |
| Any 20-session window (baseline) | -6.3% | 37% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CTXR
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroi…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 23
- Website
- www.citiuspharma.com/
Fundamentals
- 1-day range
- $0.4501$0.4699
- Market cap
- $17.62M
- P/E (trailing)
- —
- P/E (forward)
- -0.32
- EPS (trailing)
- $-2.13
- Dividend yield
- —
- Beta
- 1.03
- Avg. volume
- 527.0K
- Dividend pay date
- June 9, 2017
Forecasts
1 analyst ratings
Citius Pharmaceuticals Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CTXRCitius Pharmaceuticals Inc. Common Stock$0.46▲ 0.00%Market cap $17.62MP/E —$0.46$2.19
- LPCNLipocine Inc. Common Stock$1.56▼ 7.14%Market cap $17.56MP/E —$1.59$12.37
- NCELNewcelX Ltd. Ordinary Shares$2.5▼ 12.28%Market cap $17.98MP/E —$1.83$18.4
- MDCXMedicus Pharma Ltd. Common Stock$3.25▼ 5.25%Market cap $16.97MP/E —$0.144$2.78
- CYCNCyclerion Therapeutics Inc. Common Stock$3.36▼ 0.15%Market cap $16.67MP/E —$7.19$59.36
- SKYESkye Bioscience Inc. Common Stock$1.55▼ 2.52%Market cap $16.58MP/E —$1.5$13.28
- MRKRMarker Therapeutics Inc. Common Stock$1.04▲ 13.04%Market cap $18.67MP/E —$0.84$2.46
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CTXR Citius Pharmaceuticals Inc. Common Stock | $17.62M | — | $0.46 | ▲ 0.00% | $0.46$2.19 |
| LPCN Lipocine Inc. Common Stock | $17.56M | — | $1.56 | ▼ 7.14% | $1.59$12.37 |
| NCEL NewcelX Ltd. Ordinary Shares | $17.98M | — | $2.5 | ▼ 12.28% | $1.83$18.4 |
| MDCX Medicus Pharma Ltd. Common Stock | $16.97M | — | $3.25 | ▼ 5.25% | $0.144$2.78 |
| CYCN Cyclerion Therapeutics Inc. Common Stock | $16.67M | — | $3.36 | ▼ 0.15% | $7.19$59.36 |
| SKYE Skye Bioscience Inc. Common Stock | $16.58M | — | $1.55 | ▼ 2.52% | $1.5$13.28 |
| MRKR Marker Therapeutics Inc. Common Stock | $18.67M | — | $1.04 | ▲ 13.04% | $0.84$2.46 |
P/E shows — for peers not currently carrying a live signal of their own.
Institutional Ownership
March 31, 2026
- Total shares held
- 969.9K
- Total value held
- $818.1K
- Institutional holders
- 35
- Unknown246.2K
- Unknown167.7K
- Unknown69.9K
- Unknown60.3K
- Unknown59.0K
- Unknown55.0K
- Unknown46.4K
- Unknown44.0K
- Unknown36.8K
- Unknown29.1K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
CTXR to Attend Investor Conferences in Oct 2026
Citius Pharmaceuticals will attend investor conferences in October 2026, allowing shareholders to hear about future plans. The event may raise the company’s visibility and give management a platform to discuss strategy. The announcement does not alter current trading levels but could affect investor interest.
CTXR to Attend Investor Conferences in Oct 2026. Citius Pharmaceuticals will attend investor conferences in October 2026, allowing shareholders to hear about future plans. The event may raise the company’s visibility and give management a platform to discuss strategy. The announcement does not alter current trading levels but could affect investor interest.